| License: Creative Commons Attribution Non-commercial No Derivatives 4.0 PDF - Published Version (2MB) |
- URN to cite this document:
- urn:nbn:de:bvb:355-epub-525158
- DOI to cite this document:
- 10.5283/epub.52515
This publication is part of the DEAL contract with Wiley.
Abstract
Although modern clinical management strategies have improved the outcome of paediatric patients with severe autoimmune and inflammatory diseases over recent decades, a proportion will experience ongoing or recurrent/relapsing disease activity despite multiple therapies often leading to irreversible organ damage, and compromised quality of life, growth/development and long-term survival. ...

Owner only: item control page